Skip to Main Content
Table 3.

A. Univariate analysis of the association of PIK3CA mutations, KRAS mutations, and PTEN protein expression with clinical outcome of mCRC patients treated with the anti-EGFR monoclonal antibodies cetuximab or panitumumab. Responders are patients who achieved PR; nonresponders are PD and SD (RECIST)
PIK3CA
KRAS
PIK3CA and/or KRAS
PTEN
WT (%)Mut (%)PWT (%)Mut (%)PWT (%)Mut (%)PNormal (%)Loss (%)P
Objective response             
    Responders 22 (100) 0 (0) 0.038 20 (90.9) 2 (9.1) 0.019 20 (90.9) 2 (9.1) 0.001 17 (94.4) 1 (5.6) 0.001 
    Nonresponders 73 (82.9) 15 (17.1)  57 (65.5) 30 (34.5)  44 (50.6) 43 (49.4)  32 (50.8) 31 (42.2)  
   
B. Multivariate logistic regression of the association between PIK3CA mutations, KRAS mutations, and PTEN protein expression and objective response (any single P value is adjusted with respect to other regressors);
 
  

 
OR (95% CI for OR)
 
P
 
PIK3CA (mutated vs WT) 0.1153 (0.000–0.865) 0.0337 
KRAS (mutated vs WT) 0.0660 (0.000–0.452) 0.0029 
PTEN (loss vs normal) 0.0547 (0.001–0.430) 0.0012 
   
C. Multivariate Cox survival analysis of the association between KRAS mutations, PIK3CA mutations, and/or PTEN loss and risk of progression
 
  

 
HR (CI95% for HR)
 
P
 
KRAS (mutated vs WT) 1.4974 (0.8909–2.5170) 0.128 
PIK3CA/PTEN (at least one alterated vs normal) 1.8576 (1.1637–2.9653) 0.009 
A. Univariate analysis of the association of PIK3CA mutations, KRAS mutations, and PTEN protein expression with clinical outcome of mCRC patients treated with the anti-EGFR monoclonal antibodies cetuximab or panitumumab. Responders are patients who achieved PR; nonresponders are PD and SD (RECIST)
PIK3CA
KRAS
PIK3CA and/or KRAS
PTEN
WT (%)Mut (%)PWT (%)Mut (%)PWT (%)Mut (%)PNormal (%)Loss (%)P
Objective response             
    Responders 22 (100) 0 (0) 0.038 20 (90.9) 2 (9.1) 0.019 20 (90.9) 2 (9.1) 0.001 17 (94.4) 1 (5.6) 0.001 
    Nonresponders 73 (82.9) 15 (17.1)  57 (65.5) 30 (34.5)  44 (50.6) 43 (49.4)  32 (50.8) 31 (42.2)  
   
B. Multivariate logistic regression of the association between PIK3CA mutations, KRAS mutations, and PTEN protein expression and objective response (any single P value is adjusted with respect to other regressors);
 
  

 
OR (95% CI for OR)
 
P
 
PIK3CA (mutated vs WT) 0.1153 (0.000–0.865) 0.0337 
KRAS (mutated vs WT) 0.0660 (0.000–0.452) 0.0029 
PTEN (loss vs normal) 0.0547 (0.001–0.430) 0.0012 
   
C. Multivariate Cox survival analysis of the association between KRAS mutations, PIK3CA mutations, and/or PTEN loss and risk of progression
 
  

 
HR (CI95% for HR)
 
P
 
KRAS (mutated vs WT) 1.4974 (0.8909–2.5170) 0.128 
PIK3CA/PTEN (at least one alterated vs normal) 1.8576 (1.1637–2.9653) 0.009 

NOTE: P values measured by Fisher's exact test.

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HR, hazard ratio.

Close Modal

or Create an Account

Close Modal
Close Modal